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Few psychosocial approaches address the negative symptoms of schizophrenia, which
shares common features with depression and anxiety. Behavioral activation (BA) is
effective for addressing depression and anxiety in adults with various mental disorders.
Motivational interviewing (MI) has been successfully applied to address ambivalence
or lack of motivation toward treatment. Motivational and behavioral activation (mBA)
has been developed by incorporating the core principles from BA and MI with recent
findings on the negative symptoms of schizophrenia. In this study, we aimed to examine
the feasibility and preliminary efficacy of mBA in a non-randomized controlled pilot study
that included individuals with schizophrenia with mild to moderate negative symptoms
receiving psychiatric rehabilitation. A total of 73 individuals with schizophrenia were
recruited. Forty-seven of the participants who met the study inclusion and exclusion
criteria were assigned to either an mBA + usual psychiatric rehabilitation group (mBA)
or a usual psychiatric rehabilitation only group (treatment as usual, TAU). Administering
mBA to individuals with schizophrenia with mild to moderate negative symptoms was
feasible in a community mental health setting. Relative to TAU, mBA was associated with
large effects in reducing negative symptoms measured using the Positive and Negative
Syndrome Scale (PANSS) and the Brief Negative Symptom Scale (BNSS). However, after
considering PANSS cognitive deficits and marital status as covariates due to significant
differences in their baseline levels, the treatment effects on the BNSS were partially
observed. In addition, participants in the mBA group showed improved verbal learning
and memory compared with those in the TAU group. In individuals with schizophrenia
receiving the usual forms of psychiatric rehabilitation in a community mental health
setting, mBA appears to offer a promising adjunctive approach for addressing mild to
moderate negative symptoms. Further investigations are needed to replicate the current
findings in a randomized controlled trial.
Keywords: behavioral activation, motivational interviewing, psychosocial intervention, negative symptoms,
schizophrenia
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INTRODUCTION
Many individuals with schizophrenia experience negative
symptoms, which are a key determinant of poor functioning
and quality of life (Pogue-Geile and Harrow, 1985; Rabinowitz
et al., 2012). Negative symptoms can persist even in individuals
who participate in the usual forms of psychiatric rehabilitation
offered in the community (Buchanan, 2007). Both clinicians
and participants would benefit from a psychosocial treatment
approach that targets persistent negative symptoms and can easily
be delivered in community mental health settings. However,
the majority of psychosocial interventions focus primarily on
positive symptoms (Breier et al., 1991; Milev et al., 2005). Few
studies have reported the efficacy of psychosocial treatments for
negative symptoms (Dobson et al., 1995; Rector and Beck, 2001;
Tarrier et al., 2004; Kurtz and Mueser, 2008; Staring et al., 2013;
Velligan et al., 2015), and the estimated effect size reported in a
recent meta-analysis was small and inconsistent across studies
(Velthorst et al., 2015). Another meta-analysis indicates that
social skills training had small to moderate effects (d = 0.40; 95%
CI = 0.19, 0.61) on negative symptoms; although, the benefits
only appear to be stable for younger patients with schizophrenia
or in studies of greater design quality (Kurtz and Mueser, 2008).
Most recently, Velligan et al. (2015) reported potential treatment
gains using comprehensive psychosocial treatments for those
who have persistent and clinically significant negative symptoms.
Thus, the effective and cost-efficient treatment of negative
symptoms is a high priority when developing interventions.
A two-factor model of negative symptoms describing
experiential (avolition, asociality, and anhedonia) and emotional
expressive impairments (alogia and flat affect) has been shown
to better explain the heterogeneity of negative symptoms
in schizophrenia than a single factor model (Horan et al.,
2011; Kirkpatrick et al., 2011; Jang et al., 2016a). Due to
the establishment of a vicious cycle between the two distinct
but related domains of negative symptoms, individuals with
schizophrenia not only exhibit low base rates of behavior
and have reduced rates of positive reinforcement from the
environment (Silverstein, 2010), but also lack the opportunity to
identify, estimate the effort required, and pursue their own values
and goals (Gold et al., 2008, 2013; Strauss et al., 2011).
Even though cognitive behavioral therapy for psychosis (CBT-
p) and CBT for negative symptoms (CBT-n) take comprehensive
approaches to addressing diverse problems including positive
symptoms, depressive symptoms, dysfunctional beliefs (e.g.,
defeatist beliefs), and negative symptoms (Morrison and Barratt,
2010; Grant et al., 2012; Staring et al., 2013), we aimed to
exclusively target a two-factor model of negative symptoms using
the core principles of behavioral activation (BA) and motivational
interviewing (MI).
BA is an evidence-based treatment option for depression
(Cuijpers et al., 2007; Mazzucchelli et al., 2009), and might be
a treatment option for negative symptoms. BA may interrupt
the vicious cycle by assisting individuals with schizophrenia
to reconnect with positive experiences using daily activity
monitoring, values and goals assessment, and goal-led activity
scheduling. More importantly, BA would be a cost-efficient
option for both clinicians and individuals with schizophrenia
mainly due to its concise structure and principles (Porter et al.,
2004; Ekers et al., 2011). Porter et al. (2004) suggested that group-
format BA is a viable and effective adjunct to the usual treatment
conducted in community mental health settings for depressed
clients. Ekers et al. (2011) demonstrated that generic mental
health professionals without expertise in psychotherapy could
deliver BA in an effective manner.
Recent neuroscience data indicate that individuals with
schizophrenia have an intact capacity for experiencing here-and-
now pleasure, but experience difficulty recalling and predicting
pleasure (i.e., retrospective and prospective hedonia) with
aberrant attentional deficits to pleasurable stimuli (Strauss and
Gold, 2012; Jang et al., 2016b,c). Thus, it is speculated that
daily activity monitoring would help to allocate attention to
meaningful and pleasant daily activities that individuals with
schizophrenia have had in the recent past. At the beginning of
each session, there is an additional opportunity to recall and share
the participant’s pleasurable activities in the past week without
looking at their monitoring form. This was used to enhance
the participant’s retrospective hedonic experience. Assessments
of one’s own values and goals and implementation of value/goal-
led activities would help to link here-and-now pleasure with the
prediction of pleasure for prospective hedonistic experiences.
Given the difficulties that individuals with schizophrenia
have in goal-setting and planning, several goal domains (i.e.,
interpersonal, educational, vocational, independent living, etc.)
were provided to them in printed form. Specific activities (i.e.,
less than 5) under each goal domain were also provided in a
summarized form so that participants could voluntarily choose
among the options. Therapists also encouraged the participants
to link each activity with their own goals, and encouraged moving
slowly to the other goals and activities that they had not yet
explored. During this process, given the motivational deficits of
individuals with schizophrenia, MI becomes a core principle and
is the core method used (McCambridge and Strang, 2003).
Several adjustments were made to the original BA. These
included simplification of treatment materials (e.g., monitoring
and scheduling forms) and terms, providing greater structure
for every session, minimizing the number of forms to be
completed during the session, minimizing homework activities,
developing strategies to remember core activities (i.e., monitoring
and activating activities), slowing the pace of conversation, and
greater repetition for those with cognitive impairments.
Recent meta-analysis indicates that social skills training
is associated with some improvement in negative symptoms
(Kurtz and Mueser, 2008). In each session, brief components
of social skills training that could be delivered in the context
of the motivational and behavioral activation (mBA) group
session [i.e., speaking loud enough to be heard, practicing
(half) smiles while talking about pleasant events, listening to
others, and providing feedback to others] were incorporated to
target emotional expressivity (e.g., vocal expression, expressive
gestures, facial expression, quantity of speech). The clinicians
then provide consistent positive feedback whenever the
participants display emotional expressivity (Supplementary
Table S2).
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After the incorporation of these adjustments, BA could
assist individuals with schizophrenia to recall and monitor
pleasurable and goal-directed activities in the past and to plan and
implement a future schedule. Given extensive data supporting
the efficacy of behaviorally oriented approaches in psychiatric
rehabilitation (e.g., contingency management) for individuals
with schizophrenia with various levels of functioning (Porter
et al., 2004; Ekers et al., 2011; Granholm et al., 2015; Murphy et al.,
2015), BA would be feasible and beneficial for individuals with
schizophrenia with mild to moderate negative symptoms. Mairs
et al. (2011) reported in a small-sample pilot case study that BA
exhibited a large effect and appeared to be a promising approach
for treating the negative symptoms of schizophrenia.
To target motivational deficits or ambivalence toward
treatment, MI has recently been successfully combined with
various interventions such as cognitive remediation (Rüsch
and Corrigan, 2002; Steinberg et al., 2004; Fiszdon et al.,
2016), and has demonstrated synergistic effects. Likewise, MI
is incorporated into BA to better understand the relationships
between ambivalence about change and each participant’s goals,
values, and resistance. It is carried out by expressing empathy,
rolling with resistance, supporting self-efficacy, and developing
discrepancy whenever necessary (Miller and Rollnick, 2002).
MI is a particularly important component when assisting the
participant in his/her search for their own goals/values, potential
barriers and concerns, and for evaluating and establishing
solutions and plans (McCambridge and Strang, 2003). Since BA
and MI share common aspects (e.g., searching for values/goals
and planning for behavioral changes), MI is not only well
integrated into BA, but is expected to further help to deliver
the core components of BA to individuals with schizophrenia
with motivational deficits or ambivalence toward behavioral
change.
With these theories and findings in mind, we have developed
the mBA Program as an adjunct to psychiatric rehabilitation for
individuals with schizophrenia with mild to moderate negative
symptoms. This is a brief manual-based psychological approach
that incorporates BA principles and MI components targeting a
two-factor model of negative symptoms.
For Stage I-A of intervention development, as suggested by
Onken et al. (2014), the authors translated and modified the
Brief Behavioral Activation Treatment for Depression (BATD)
manual by Lejuez et al. (2001) and evaluated its feasibility
in eight community-dwelling individuals with schizophrenia
with mild to moderate negative symptoms using a 12-session
group format (Choi et al., 2014), with a low dropout rate
(n= 1, employed). Following Stage I-A, the authors incorporated
feedback from participants and clinicians, and the program was
revised accordingly, with the BATD manual being simplified to a
10-session group format (Choi et al., 2014). With these revisions,
the mBA program was finally established for a Stage I-B pilot trial.
We hypothesized that the mBA program would be feasible
and tolerable to individuals with schizophrenia with mild or
moderate negative symptoms participating in community-based
psychiatric rehabilitation. In addition, it was hypothesized that
the mBA group would have lower levels of negative symptoms
compared with the treatment as usual (TAU) group. Lastly,
given that extensive research supports the link between negative
symptoms, daily functioning, and cognitive impairments (Green,
1996; Velligan et al., 1997; Green et al., 2000; Foussias and
Remington, 2010), and the mBA program includes repetitive
practice of attending and recalling one’s own activities and
planning, we explored whether mBA was associated with
recovery in neurocognition.
MATERIALS AND METHODS
Participants
Seventy-three participants were recruited from community
mental health centers and day hospitals from September 2012
until January 2015. Inclusion criteria for the participants
were as follows (Buchanan, 2007): (1) a primary diagnosis of
schizophrenia or schizoaffective disorder, (2) aged between 18
and 65 at the time of pre-testing, (3) mild to moderate negative
symptoms [greater than 3 on at least two negative symptom
items from the Positive and Negative Syndrome Scale (PANSS)],
and (4) stably prescribed psychotropic medications for at least
the previous 6 months. Exclusion criteria included (1) a history
of organic brain syndrome, seizures, or traumatic brain injury,
(2) current comorbid disorders such as mental retardation,
or current alcohol or other substance abuse/dependence,
(3) more than moderate positive symptoms (greater than 4
on PANSS positive symptom items), (4) more than mild
depressive symptoms (greater than 3 on PANSS depressive
symptom items), (5) receiving psychological services that
include behavioral activation components, and (6) risk of
self-harming or homicide. There were no differences in
demographic variables between the two groups, except for
marital status and baseline PANSS cognitive symptoms (Table 1),
which were included as covariates in subsequent analyses
(Table 1).
Procedures
The participants in this pilot study were recruited from various
community mental health centers located in urban areas in
South Korea. Prior to pre-treatment assessment, all participants
provided informed consent. Local Institutional Review Boards
approved this study. After the pre-treatment assessment, 47
participants who met study inclusion criteria were allocated to
either the mBA (n = 23) or the TAU group (n = 24) (Figure 1)
based on negative symptom scores. Group allocation was made
alternately from active group to control group, and thus the
most subjects were assigned to the active group or the control
group based on their interest to participate in the current study
after having received information on the study. Regardless of the
allocated group, participants attended the centers for psychiatric
rehabilitation program. About 10 weeks after completing the
mBA program, the post-treatment assessment was administered
to mBA and TAU groups over similar time frames. Of the 49
participants, one participant (of 23) in the treatment group was
dropped due to job conflicts, while five participants (of 24) in the
control group were dropped for reasons such as hospitalization,
service refusal, and losing contact.
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TABLE 1 | Baseline characteristics of participants.
Treatment Control group t or χ2
group (n = 23) (n = 24)
Age, M (SD) 40.43 (11.72) 44.38 (10.77) −1.20
Age of onset, M (SD) 24.22 (7.03) 24.29 (8.39) −0.03
Years of education, M (SD) 12.04 (2.67) 11.21 (3.58) 0.90
Gender, n (%)
Men 11 (47.83) 12 (50.00) 0.02
Women 12 (52.17) 12 (50.00)
Marital status, n (%)
Married 1 (4.35) 9 (37.50) 11.05∗∗
Single 18 (78.26) 8 (33.33)
Divorced/other 4 (17.39) 7 (29.17)
Medication, n (%) 23 (100.00) 24 (100.00) –
PANSS, M (SD)
Negative 18.17 (3.66) 18.38 (4.21) −0.17
Excitement 6.52 (1.93) 6.83 (2.06) −0.54
Cognitive 11.22 (2.56) 13.08 (3.36) −2.14∗
Positive 8.57 (2.76) 8.46 (3.48) 0.12
Depression 9.52 (2.76) 9.17 (3.12) 0.41
Total 68.26 (9.86) 69.67 (14.13) −0.39
∗p < 0.05; ∗∗p < 0.01.
FIGURE 1 | Flow chart of participants.
Motivational and Behavioral Activation
The mBA program for negative symptoms was provided by the
researchers in our team. Fidelity was assessed with a random
visit (92.31%; Supplementary Table S1). Participants received ten
60- to 70-minute group sessions either once or twice weekly.
The main purpose of mBA was to increase the level of routine
and social activities that participants identified as pleasurable,
meaningful, and valuable. Specifically, mBA assisted participants
(1) to monitor daily activities in the previous week, (2) to set
goals, (3) to identify and plan daily activities that fit their own
goals, (4) to administer their own goal-led activities, and (5) to
identify and address barriers to achieving their goal-led activities.
Throughout the mBA program, participants were expected
to practice (1) goal setting, (2) monitoring of activities and
remembering pleasurable and meaningful activities, (3) goal-led
activity planning, and (4) problem-solving skills. Therapists were
expected to persistently use MI techniques such as employing
open-ended questions, using positive feedback, reflection, and
summarizing the participant’s words, especially for participants
with ambivalence or lack of motivation toward the treatment.
In addition to target emotional expressivity in the context of
mBA, brief components of social skills training [i.e., speaking
loud enough to be heard, practicing (half) smiles while talking
about pleasant events, listening to others, and providing feedback
to others] were practiced in each session. The content of each
session of mBA is presented in Supplementary Table S2.
Measures
Participants each completed a semi-structured interview-based
psychiatric symptom assessment, self-report questionnaires for
motivation, and brief neurocognitive assessment batteries. All
interviews were conducted by licensed clinical psychologists and
clinical psychology graduate students who obtained satisfactory
intra-class correlations (ICCs).
Psychiatric Symptoms
The PANSS (Kay et al., 1987) was administered to evaluate
the severity of psychiatric symptoms. Each item was scored on
a 1 (absent symptom) to 7 (extreme symptom) Likert scale.
Five factor scores were calculated for the PANSS, i.e., Negative
symptoms, Excitement, Cognition, Positive symptoms, and
Depression (Bell et al., 1994; Lindenmayer et al., 1994, 1995). In
the current study, Cronbach’s α for each subscale was as follows:
Negative symptoms= 0.87, Excitement= 0.64, Cognition= 0.69,
Positive symptoms = 0.70, and Depression = 0.67. ICCs for
each subscale were as follows: Negative symptoms = 0.93,
Excitement= 0.69, Cognition= 0.95, Positive symptoms= 0.98,
Depression= 0.50.
The Brief Negative Symptom Scale (BNSS) is a semi-
structured clinical interview that measures the severity of
negative symptoms in schizophrenia and schizoaffective disorder
(Kirkpatrick et al., 2011). The BNSS was based on a two-
factor model of negative symptoms, consisting of experiential
impairment (anhedonia, asociality, and avolition) and expressive
impairment (alogia and blunted affect) (Horan et al., 2011;
Strauss et al., 2012). Thirteen items, each ranging from absence
of symptom (0) to extremely severe symptom (6) in motivation–
pleasure and emotional expressivity subscales, were assessed
over a time period of 1 week. Since the BNSS was translated
into Korean and was available after the initiation of this trial,
we obtained BNSS data from thirty participants (n = 14 for
mBA, n = 16 for TAU). In the current study, Cronbach’s
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α for the motivation–pleasure subscale was 0.93 and for
the emotional expressivity subscale was 0.86. ICCs for each
subscale were as follows: motivation–pleasure = 0.68, emotional
expressivity= 0.89.
Neurocognitive Function
The Korean Auditory Verbal Learning Test (K-AVLT) was
designed to evaluate short-term memory, auditory verbal
memory, and learning strategies (Rey, 1964). Cheong et al. (1999)
revised and validated the Korean version. After listening to 15
words presented verbally, participants were asked to complete
free recall trials immediately and after a 30-minute delay, and a
recognition trial.
Trail Making Test A and B (TMT-A, B) are included in the
Halstead–Reitan neuropsychological test battery (Reitan, 1992).
In part A, subjects were asked to sequentially connect dispersed
digits (1–25) to measure psychomotor speed and attention. In
part B, subjects were required to connect 15 digits and 14 letters
alternately in ascending order, to measure executive function
related to frontal lobe activity such as mental flexibility and
visuospatial working memory. Times to complete the tasks and
the number of errors constituted the test scores. If subjects
exceeded 90 s in part A or 300 s in B, the data were excluded from
the analysis.
The Coding (CD) subtest in the Wechsler Adult Intelligence
Scale–Fourth Edition (WAIS-IV; Wechsler, 2008; Hwang
et al., 2012) was used to measure visual-motor coordination,
persistence of concentration, and short-term visual memory.
Subjects were required to copy as many symbols as possible
within 120 s using a key. Total scores were based on the number
of correctly matched items.
Premorbid Intelligence Quotients
To estimate premorbid IQ, the Information subtest (IN) in
the K-WAIS-IV (Hwang et al., 2012) was administered. Items
covered a range of common, realistic, and general knowledge.
Premorbid intelligence was estimated using an algorithm from
the Korea Premorbid Intelligence Estimate for the WAIS-IV
(KPIE-IV; Kim et al., 2015).
RESULTS
Feasibility
Dropout rates (4.35% for mBA vs. 20.83% for TAU) were similar
between the mBA and the TAU groups (χ2 = 2.87, p = 0.09),
indicating that mBA would be tolerable and feasible to administer
to individuals with schizophrenia with mild to moderate negative
symptoms participating in the usual psychiatric rehabilitation
services.
Effects of mBA on Psychiatric Symptoms
We conducted repeated-measures ANOVAs for negative
symptom scores and other psychiatric symptoms (i.e., positive,
depressive, cognitive, and excitement symptoms) measured
using the PANSS and the BNSS, with treatment and control
groups as the between-subjects factor (mBA vs. TAU) and time
as the within-subjects factor (pre- and post-) (Table 2). These
analyses revealed no significant main effect of group on any
PANSS subscale except for the negative scale, F(1,39) = 4.15,
p < 0.05, and cognitive scale, F(1,39) = 23.87, p < 0.001. There
were significant interaction effects of group by time on scores
for the negative symptoms subscale, F(1,39) = 10.10, p < 0.01,
cognitive symptoms subscale, F(1,39) = 10.45, p < 0.01, and
depression subscale, F(1,39) = 10.99, p < 0.01 (Table 2). The
findings indicate that participants in the mBA improved their
negative, cognitive, and depressive symptoms compared to
those in the TAU group. Even after considering baseline PANSS
cognitive symptoms or marital status as a covariate, all of the
significant findings reported above were maintained.
In addition, there was no significant main effect of group
on the BNSS score. However, there were significant interaction
effects of group by time on the motivation and pleasure subscale,
F(1,28) = 4.72, p < 0.05, and emotional expressivity subscale,
F(1,28) = 4.35, p < 0.05 (Table 2). The findings indicate that
participants in the mBA group improved their BNSS subscale
scores when compared to those in the TAU group. However, after
considering baseline PANSS cognitive symptoms as a covariate,
the treatment effect on BNSS motivation and pleasure subscales
disappeared (p = 0.12). To consider marital status as a covariate,
we examined the study hypotheses only using participants who
were single. Using these participants, the treatment effects on the
BNSS subscales disappeared (n= 11 for mBA; n= 5 for TAU).
To delineate the significant interaction effects, we calculated
a partial eta-squared measure of effect size for use in ANOVA
(Cohen, 1988; Miles and Shevlin, 2001) with general rules of
thumb for the magnitude of the effect sizes, i.e., small (∼0.01),
medium (∼0.06), and large (∼0.14). The effect sizes for the
treatment group were mostly large for the above-mentioned
negative symptoms, cognition, and depressive symptoms in the
PANSS and BNSS (Table 2).
Effects of mBA on Neurocognitive
Function
We conducted repeated-measures ANOVAs on neurocognitive
function with the treatment and control groups as the between-
subjects factor (Group) and time (pre-, post-) as the within-
subjects factor (Table 3). The analyses revealed no significant
main effect of group on neurocognitive function. There was a
significant interaction effect of group by time on the K-AVLT
total score, F(1,39) = 5.37, p < 0.01 (Table 2). The effect size
for the treatment group on the K-AVLT total score was medium
(Table 3).
DISCUSSION
We have developed a manual-based brief psychosocial
intervention that incorporates the core principles of BA
and MI with recent findings on negative symptoms to target the
two-factor components of negative symptoms in schizophrenia.
The current study is the first to investigate the feasibility and
efficacy of mBA as an adjunct to psychiatric rehabilitation for
individuals with schizophrenia with mild to moderate negative
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TABLE 2 | Effects of mBA on psychiatric symptoms.
Measure Group Pre Post Main effect Interaction effect Effect Size
M (SD) M (SD) Group F Time F Group × time F Partial η2
PANSSa
Negative Treatment 18.05 (3.70) 14.09 (4.74) 4.15∗ 12.49∗∗ 10.10∗∗ 0.21
Control 18.79 (4.50) 18.58 (5.07)
Excitement Treatment 6.50 (1.97) 6.55 (2.13) 0.48 0.48 0.33 0.01
Control 6.63 (1.80) 7.11 (2.05)
Cognitive Treatment 11.36 (2.52) 9.82 (2.68) 23.87∗∗∗ 0.21 10.45∗∗ 0.21
Control 13.00 (3.04) 15.05 (3.24)
Positive Treatment 8.68 (2.77) 9.00 (3.34) 0.01 3.15 1.50 0.04
Control 7.90 (2.94) 9.63 (3.42)
Depression Treatment 9.59 (2.81) 8.96 (2.79) 0.75 3.56 10.99∗∗ 0.22
Control 8.90 (3.36) 11.21 (3.87)
BNSSc
Motivation and pleasure Treatment 21.29 (8.67) 16.86 (7.86) 1.07 3.56 4.72∗a 0.14
Control 21.69 (7.60) 22.00 (7.53)
Emotional expressivity Treatment 18.50 (5.97) 15.29 (7.17) 0.12 0.84 4.35∗b 0.14
Control 17.13 (8.35) 18.38 (7.36)
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
aAfter considering baseline PANSS cognitive symptoms as a covariate, the treatment effect on the BNSS motivation and pleasure subscale disappeared (p = 0.12).
bThe treatment effect on the BNSS subscales disappeared (n = 11 for mBA, n = 5 for TAU) when examining the study hypotheses only using participants with single
marital status.
cBNSS sample size (n = 14 for mBA, n = 16 for TAU).
symptoms, compared with TAU. In accordance with Onken et al.
(2014), the current study is considered to be Stage I-B of an
intervention development process.
The results indicate that the dropout rate for mBA was
minimal compared with TAU (4.35% for mBA; 20.83% for
TAU). This may support its feasibility for community dwelling
individuals with schizophrenia. Velligan et al. (2015) reported
a dropout rate of 34.6% in their recent randomized controlled
trial (RCT) of the MOtiVation and Enhancement (MOVE)
program conducted over 9 months. Given that the MOVE trial
targeted persistent and clinically significant negative symptoms
in a comprehensive manner over a longer treatment period, it
is speculated that the concise structure of mBA (e.g., principles
and techniques), the shorter treatment duration, and the
participant characteristics (mild to moderate negative symptoms,
regular participation in psychiatric rehabilitation program)
would permit greater treatment survival rates. Even though a
10-session time frame is quite challenging for tackling negative
symptoms, the repetition of exercises and gradual addition
of treatment components across sessions appeared to provide
enough opportunities for gaining treatment effects. Another
possible reason for the differential drop-out rates between the
mBA and TAU groups may be the potential extraneous variable
affecting the allocation of the participants, as this was a non-
randomized trial and the mBA and TAU groups were formed
alternately. Thus, in this procedure, participants might have
known the group they were allocated to prior to group allocation.
This may have resulted in selection bias; for example, participants
who had greater motivation for change may have been more
likely to be assigned to the mBA group than the TAU group.
To examine the potential impacts of different demographic
characteristics (i.e., marital status) and psychiatric conditions
(i.e., PANSS cognitive impairments factor) on drop-out rates, we
compared those who dropped out to those who did not drop-out
in terms of demographic and symptom variables. There were no
differences in age, gender, age of onset, years of education, and
PANSS subscales. The only observed difference was in marital
status (χ2 = 10.755, p = 0.005). Interestingly, none of the single
participants dropped out of either group. Even though marital
status was not related to the primary study findings, a future
study should examine the relationship between marital status and
drop-out rates in the mBA.
As hypothesized, mBA was associated with large treatment
effects on negative symptoms, cognition, and depressive
symptoms in the PANSS and the BNSS emotional expressivity
subscale even after considering the PANSS cognitive factor. It
is notable that the large effects gained within a shorter period
(10 weeks) were comparable with those of other approaches
conducted over a longer period (Kurtz and Mueser, 2008;
Velligan et al., 2015; Velthorst et al., 2015). It is speculated that
the comparable treatment gains might be attributable to the
sample characteristic (mild to moderate negative symptoms)
and/or treatment characteristics explicitly targeting a two-factor
theory of negative symptoms.
After considering the PANSS cognitive factor, the treatment
effects on the BNSS emotional expressivity were maintained
but motivation and pleasure subscales disappeared. Since the
BNSS was administered to a subsample of the study participants
(n = 14 for mBA and n = 16 for TAU), this finding should be
cautiously interpreted because of its lack of power in detecting
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TABLE 3 | Effects of mBA on neurocognitive function.
Measure Group Pre Post Main effect Interaction effect Effect size
M (SD) M (SD) Group F Time F Group × time F Partial η2
Coding Treatment 34.37 (7.73) 37.42 (8.85) 0.18 12.18∗∗ 0.00 0.00
Control 35.45 (8.70) 38.53 (8.06)
Digit span Treatment 44.05 (10.18) 44.42 (9.60) 1.11 4.05 2.50 0.07
Control 39.49 (10.37) 42.56 (8.75)
K-AVLT total Treatment 28.95 (13.19) 41.21 (16.44) 2.16 14.30∗∗ 5.37∗ 0.13
Control 28.11 (10.79) 31.05 (11.24)
TMT-A Treatment 38.18 (11.76) 43.28 (10.26) 0.39 7.82∗∗ 0.02 0.00
Control 35.74 (16.87) 40.34 (16.83)
TMT-B Treatment 39.46 (15.65) 41.82 (16.53) 2.10 0.03 0.43 0.01
Control 32.21 (22.39) 30.79 (24.27)
∗p < 0.05; ∗∗p < 0.01.
potential therapeutic benefits. However, there are several possible
interpretations. First, it is speculated that the PANSS cognitive
factor might share common aspects (e.g., cognitive deficits)
with motivation and pleasure (Bell et al., 1994; Foussias et al.,
2014), rather than with emotional expressivity. Thus, in future
studies, cognitive symptoms of allocated participants should
be counter-balanced. Second, to target emotional expressivity,
mBA incorporated brief components of social skills training
[e.g., speaking loud enough to be heard, practicing (half) smiles
while talking about pleasant events, listening to others, providing
feedback to others, clinician’s positive and corrective feedback],
of which repetitive practice in the context of BA group session
may result in robust improvement on the BNSS emotional
expressivity, even after considering cognitive symptoms. To
clarify whether mBA would lead to incremental benefits beyond
social skills training on the two distinct factors of negative
symptoms, mBA should be compared with social skills training
in a future study.
In addition, even though we recruited participants with mild
to moderate negative symptoms and less-than-mild depressive
symptoms to avoid comorbidity between negative symptoms and
depressive symptoms, mBA was associated with improvement
in depressive symptoms. Given that this is a preliminary
study with limitations regarding the investigation of underlying
mechanisms, common aspects between negative symptoms and
depressive symptoms affected by mBA should be explored in a
future study.
However, the current findings were gained from a Stage I-B
pilot trial, and thus should be replicated in an RCT trial.
Interestingly, even though it was not specifically predicted,
mBA was associated with a medium effect on verbal learning
and memory measured by the K-AVLT total score. Even though
this finding should be interpreted cautiously due to the absence
of a priori hypothesis testing, it can be speculated that verbal
learning and memory might mediate the treatment gains from
mBA as they have functional implications in individuals with
schizophrenia (Green et al., 2000) and depression (Clark et al.,
2009). A future study should determine whether treatment
components of the mBA (e.g., recalling pleasurable and
meaningful activities) are related to improvements in verbal
learning and memory.
Several limitations should be noted. With a non-RCT,
the causality of mBA on outcome variables should not be
assumed and needs to be replicated in a future RCT study.
Second, the PANSS negative symptoms factor was used as an
inclusion criterion for mild to moderate negative symptoms
in the current study. However, the PANSS is often regarded
as an inadequate measure of negative symptoms, especially
for experiential negative symptoms. Although in our data,
the PANSS negative symptom factor scores at baseline were
strongly correlated with the BNSS motivation and pleasure
subscale scores (r = 0.727, p < 0.001), in future trials of
mBA, study inclusion criteria should be revised to assess for the
primary target of mBA. Third, the current study did not include
follow-up assessments. Thus, a future study needs to evaluate
whether the treatment gains reported in the current study are
maintained. Fourth, it should be determined whether the 10-
session format is sufficient for mastery of the core treatment
components by individuals with schizophrenia with mild to
moderate negative symptoms. Even though the major purpose
of the current study was to prove the concept and evaluate
the preliminary efficacy, future trials should evaluate whether
longer treatment sessions produce larger treatment gains. Finally,
clinicians have reported that MI is a critical component while
they are assisting and encouraging participants to search for
their own goals/values, to link each activity with their own goals,
and to encourage moving slowly to other unexplored goals and
activities. However, there were no specific measures regarding
these factors included in the study design. Thus, in a future
study, specific scales (e.g., the Stage of Change Readiness and
Treatment Engagement Scale) should be included to examine
these phenomena.
Despite the limitations mentioned above, the current findings
support the notion that mBA would be a promising adjunctive
approach to the usual psychiatric rehabilitation services delivered
in community mental health settings for addressing mild to
moderate negative symptoms in individuals with schizophrenia.
As a next step (Stage II), RCT trials should replicate the
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current findings to confirm the causality of mBA in improving
mild to moderate negative symptoms. We believe that the
current findings will facilitate the development of an effective
psychosocial treatment for individuals with schizophrenia with
mild to moderate negative symptoms who participate in
community based psychiatric rehabilitation services.
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